The benefits of popular weight loss pill Acomplia, also known as rimonabant, no longer outweigh its risks – and it should not be allowed to be sold in the European Union, The European Medicines Agency (EMEA) has concluded.

In fact, taking Acomplia more than doubles your risk of psychiatric disorders such as depression.

Acomplia has been authorised in the EU since June 2006, as a weight loss pill to compliment diet and exercise to treat obese or overweight patients.

A new obesity pill, set to launch in the next few years, is twice as effective as currently approved weight loss drugs. To read more, Click Here: New Diet Pill Doubles Weight Loss

Warnings about psychiatric side effects, in particular depression, have been included in the product information since Acomplia was first authorised. But since then, warnings have had to be upgraded as experts became more aware of the serious mental health side effects associated with the diet pill.

The new findings show that the drug is less effective than previously thought; plus the side effects are worse and more common.

That’s why the EMEA now recommend that prescribers should not issue any new prescriptions for Acomplia and should review the treatment of patients currently taking the medicine.

If you are currently taking Acomplia, consult your doctor or pharmacist to discuss your treatment. Although there is no need for you to stop treatment with Acomplia immediately, patients who wish to stop can do so at any time.

A new report has revealed the five simple things you should do every day to boost your mood and mental wellbeing. To find out what they are, Click Here: How to Get Your Mental Health Five a Day